Trihexyphenidyl

Trihexyphenidyl
Clinical data
AHFS/Drugs.com Monograph
MedlinePlus a682160
Pregnancy
category
  • US: C (Risk not ruled out)
Routes of
administration
Oral, as tablet or elixir
ATC code
Legal status
Legal status
Pharmacokinetic data
Biological half-life 3.3-4.1 hours
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
ECHA InfoCard 100.005.105
Chemical and physical data
Formula C20H31NO
Molar mass 301.466 g/mol
3D model (JSmol)
  (verify)

Trihexyphenidyl (Artane, Apo-Trihex, Parkin, Pacitane), also known as benzhexol, Ariane, and trihex, is an antiparkinsonian agent of the antimuscarinic class. It has been in clinical usage for decades.

Uses

Trihexyphenidyl is used for the symptomatic treatment of Parkinson's disease in mono and combination therapy. It is active in postencephalitic, arteriosclerotic, and idiopathic forms. The drug is also commonly used to treat extrapyramidal side effects occurring during antipsychotic treatment. It reduces the frequency and duration of oculogyric crises as well as of dyskinetic movements and spastic contractions. Trihexyphenidyl may improve psychotic depression and mental inertia frequently associated with Parkinson's disease and symptomatic problems caused by antipsychotic treatment.

The drug cannot cure Parkinson's disease, but may provide substantial alleviation of symptoms.An estimated 50 to 75% of people with Parkinson's disease will react positively and experience a 20 to 30% symptomatic improvement. To increase therapeutic activity trihexyphenidyl is often given concomitantly with levodopa, other antimuscarinic or antihistaminic (e.g. diphenhydramine) agents. Combination treatment with dopaminergic agonists such as cabergoline is also possible. This is often termed a 'multidimensional approach'. It has also been prescribed for essential tremor and akathisia.

Contraindications

Contradindications include:

Adverse effects

Dose-dependent side effects are frequent, but typically lessen over time as the body adapts to the medication. All of the following symptoms considered, Artane has been shown to dramatically and consistently improve neurologic defects in people aged 16-86 over the course of five years.[1] People who are older or who psychiatric conditions may become confused or develop delirium. Side effects include but are not limited to:[2]

Trihexyphenidyl is a pregnancy category C drug. It is advised to only use with caution if benefits outweigh risks.[4]

Overdose

Trihexyphenidyl (THP) and other antiparkinsonian drugs are known to be substances of abuse. This is true both in abusers of other substances and in chronic schizophrenics, the latter being infrequent abusers of other drugs. Trihexyphenidyl mimics an atropine intoxication with mydriasis, dryness of mucous membranes, red face, atonic states of bowels and bladder, and hyperthermia in high doses. Central consequences are agitation, confusion, and hallucinations. An untreated overdose may be fatal, particularly in children. Premortal signs are respiratory depression and cardiac arrest. A specific antagonist is physostigmine which combines a peripheral and a central action. Carbachol can be used to treat atonic bowel and bladder. The vital functions should be monitored and stabilized. It may be necessary to treat hyperthermia with cooling blankets. Clinical case reports have repeatedly shown overdose of Trihexyphenidyl alongside other substances.

Interactions

Pharmacology

The exact mechanism of action in parkinsonian syndromes is not precisely understood, but it is known that trihexyphenidyl blocks efferent impulses in parasympathetically innervated structures like smooth muscles (spasmolytic activity), salivary glands, and eyes (mydriasis). In higher doses direct central inhibition of cerebral motor centers may contribute. In very high doses central toxicity as seen in atropine overdose is noted. It binds to the M1 muscarinic receptor[5] and possibly the dopamine receptor.[6] Trihexyphenidyl is rapidly absorbed from the gastrointestinal tract. The onset of action is within 1 hour after oral dosing. The peak activity is noted after 2 to 3 hours.[7] The duration of action of one single dose is 6 to 12 hours in a dose dependent manner. It is excreted in the urine, probably as unchanged drug. More precise data in animals and humans have so far not been determined.[8][9]

Chemistry

Trihexyphenidyl can be synthesized in two ways, one linear and one convergent synthesis.

In the first way, the initial 2-(1-piperidino)propiophenone is synthesized in turn by the aminomethylation of acetophenone using paraformaldehyde and piperidine in a Mannich reaction. In the second step the 2-(1-piperidino)propiophenone is reacted with cyclohexylmagnesium bromide in a Grignard reaction.[10]

Artane linear and convergent synthesis

History

Artane, or its generic form Trihexyphenidyl HCL, was approved by the FDA on June 25th, 2003 for the clinical use of all types of parkinsonism.[11]However, it has been clinically relevant in trials pertaining to Parkinson's disease since 1949.[12] Artane is an anticholinergic drug which is prescribed by doctors throughout the world. It is also abused, typically in combination with other drugs or delicate pharmaceutical agents. Prisons in Iraq were among the places where abuse was obvious, along with within communities of Iraqi soldiers.

Society and culture

Recreational use

In a 2008 news report, trihexyphenidyl was seen to be used for recreational purposes among Iraqi soldiers and police, among other prescription drugs. The report states that the drugs were taken to relieve combat stress.[13] Although that may be the case for some, others used Artane as a substitute or more intense version of LSD. This was especially prevalent in the 1960's, according to a report in "The New Yorker". Similarly to those in Iraqi forces, some of the appeal was that the individual may retain partial control while under the influence.[14]

The neurologist Oliver Sacks reports using the drug recreationally in the 1960s.[15] He states to have taken upwards of twenty pills knowing full well the drug was intended for people with Parkinson's. More recounts of Dr. Sack's experiences - including experimentation with mescaline, psilocybin, LSD, and probably DMT [16] - have been compared in his novel Hallucinations (book)

Research

Equivocal preliminary results from small studies exist for:

See also

References

  1. Doshay, L. J., K. Constable, and A. Zier. "Five year follow-up of treatment with trihexyphenidyl (Artane): Outcome in four hundred eleven cases of paralysis agitans." Journal of the American Medical Association 154.16 (1954): 1334-1336.
  2. "Trihexyphenidyl". Web MD. First Databank Inc.
  3. TRIHEXYPHENIDYL http://toxnet.nlm.nih.gov/cgi-bin/sis/search/r?dbs+hsdb:@term+@rn+@rel+144-11-6
  4. "trihexyphenidyl (Rx)". Medscape.
  5. Giachetti, A.; Giraldo, E.; Ladinsky, H.; Montagna, E. (1986). "Binding and functional profiles of the selective M1 muscarinic receptor antagonists trihexyphenidyl and dicyclomine". British Journal of Pharmacology. 89 (1): 83–90. PMC 1917044Freely accessible. PMID 2432979. doi:10.1111/j.1476-5381.1986.tb11123.x.
  6. Berke, J. D.; Hyman, S. E. (2000). "Addiction, dopamine, and the molecular mechanisms of memory". Neuron. 25 (3): 515–532. PMID 10774721. doi:10.1016/S0896-6273(00)81056-9.
  7. "Trihexyphenidyl Hydrochloride". Drugs.com.
  8. Watson Laboratories Inc. trihexyphenidyl hydrochloride tablets, USP. prescribing information. Corona, CA; 2005 May.
  9. AHFS drug information 2006. McEvoy GK, ed. Trihexyphenidyl. Bethesda, MD: American Society of Health-System Pharmacists; 2006:1256.
  10. Weiss, Martin J., and Maurice D. O'Donoghue. "Synthesis of Certain 3-Hydroxy-3-phenylpropylsulfonium Salts. Sulfonium Analogs of Artane (Trihexyphenidyl) and Pathilon (Tridihexethyl Iodide)." Journal of the American Chemical Society 79.17 (1957): 4771-4776.
  11. Katz, Russell; Feeney, John; Ressler, Timothy; David, Paul. "Approval Package for Application No. 6-773/36" (PDF). Access Data from the Food and Drug Association. FDA. Retrieved 8 May 2017.
  12. Doshay, L. J., and Constable, K.: Artane Therapy for Parkinsonism, J.A.M.A. 140:1317 (Aug. 27) 1949
  13. Mudhafer Al-Husaini; Erica Goode (2008-12-20), Abuse of Prescription Drugs Rises Among Stressed Iraqi Soldiers, New York Times
  14. Sacks, Oliver. "Altered States". The New Yorker. Condé Nast. Retrieved 7 May 2017.
  15. Oliver Sacks shares his hallucinations, Guardian, 2012-10-30
  16. Sacks, Oliver (2012). Hallucinations. Ch. 6: Random House Inc.
  17. Sanger, T. D.; Bastian, A.; Brunstrom, J.; Damiano, D.; Delgado, M.; Dure, L.; Gaebler-Spira, D.; Hoon, A.; Mink, J. W.; Sherman-Levine, S.; Welty, L. J.; Child Motor Study, G. (2007). "Prospective Open-Label Clinical Trial of Trihexyphenidyl in Children with Secondary Dystonia due to Cerebral Palsy". Journal of Child Neurology. 22 (5): 530–537. PMID 17690057. doi:10.1177/0883073807302601.
  18. Tarnopolsky, Mark, and Rashid Alshahoumi. "Complex I Deficiency." Mitochondrial Case Studies: Underlying Mechanisms and Diagnosis (2015): 257.
  19. Carranza-del Rio, Jorge, et al. "Use of trihexyphenidyl in children with cerebral palsy." Pediatric neurology 44.3 (2011): 202-206.
  20. Jeong, Ho Hyun, et al. "A Case Study on the Use of Trihexyphenidyl, Korean Medical Treatment for the Control of Sialorrhea in Patients with Amyotrophic Lateral Sclerosis (ALS)※." The Acupuncture 30.2 (2013): 73-79.

 This article incorporates public domain material from the United States Department of Health and Human Services document "Toxnet:Trihexyphenidyl" (retrieved on 8 May 2017).

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.